The global POC diagnostics market (excluding the blood glucose monitoring kits market) is dominated by Roche Diagnostics (Switzerland), Alere, Inc. (U.S.), Siemens AG (Germany), and Beckman Coulter, Inc. (U.S.). These four companies accounted for a share of ~72% of the global POC diagnostics market (excluding the blood glucose monitoring kits market) in 2012. Roche Diagnostics is the leader in the POC diagnostics market (excluding the blood glucose monitoring kits market) with a share of ~25% and is expected to lead the market in next five years as well. The company’s diagnostic portfolio includes 196 instruments, 4,046 different reagent kits, and 170 different types of consumables including pipettes and cuvettes. Roche has 26 manufacturing sites including 17 pharmaceuticals, seven diagnostic, and two joint sites. It has a large work force and as of 2013, employed ~28,961 people. The company’s wide range of product and service offerings coupled with its wide geographic presence enables it to maintain its leading position in the global POC diagnostics market. Furthermore, the company focuses on product innovations and new product launches as its key business strategy, to ensure its growth in the global POC diagnostics market.

Alere, Inc. (U.S.) held second position in the POC diagnostics market. The company’s extensive patent portfolio and a comprehensive range of products in the field of POC diagnostics serves as an important factor for its future growth. Being a leading developer of innovative diagnostic devices facilitates the company to combine its near-patient monitoring tools with value-added healthcare services to improve and enhance healthcare for patients. Primarily, the company focuses on three growth strategies, namely, geographic expansion, new product launch, and partnerships. Moreover, through various campaigns, Alere increasingly focuses on raising awareness about the use of POC products among patients across the globe. In order to increase its share in the global POC diagnostics market, the company has been concentrating on acquisitions as its key business strategy.

Similarly, the global blood glucose monitoring kits market is dominated by Roche Diagnostics Limited (U.K.), Johnson & Johnson (U.S.), Bayer Healthcare AG (Germany), and Abbott Laboratories, Inc. (U.S.) Roche Diagnostics is the leader in the blood glucose monitoring kits market with a share of ~29% and is expected to rule the market in next five years as well. The company has a strong geographic presence and distribution network in Europe, the Middle East and Africa (EMEA), North America, the Asia-Pacific, Latin America, and Japan. Its leading position is mainly due to the large product offering and popularity of the Accu-Chek brand. To maintain its position in the blood glucose monitoring kits market, the company aims at innovations as its major strategy.

https://www.marketsandmarkets.com/Market-Reports/point-of-care-diagnostic-market-106829185.html

Johnson & Johnson (U.S.) ranks second in the global blood glucose monitoring kits market and is expected to a give stiff competition to Roche in the next five years. This large share is attributed to the strong presence of the company in more than 275 operating companies in 60 countries and 146 manufacturing facilities across the U.S., Europe, Western Hemisphere (excluding the U.S.) and Africa, and the Asia-Pacific region. Moreover, the popularity of the OneTouch brand has enabled Johnson & Johnson to compete strongly in the blood glucose monitoring kits market. Since the past few years, the company has been focusing on the introduction of new blood glucose monitoring products in order to strengthen its position in the global market.